High throughput screening market is expected to witness a lucrative growth during the forecast period owing to the expected patent expiration of important biologics, increasing application of high throughput screening such as rapid identification of active compounds, genes and antibodies which are responsible for alteration of rapid bimolecular pathways, reduced cost in the drug discovery process and identification of potential lead compounds as a result of high throughput screening, and latest findings in proteomics and genomics resultant of the success of human genome project have created high potential for high throughput screening market. Furthermore, increasing utilization rate of throughput screening technologies by pharmaceutical companies in screening of compound libraries, rising technological advancements in high throughput screening techniques, increasing investment by drug discovery organizations and focus on up gradation of software and hardware used in high content screening technologies are also expected to boost the growth of high throughput screening techniques in the next seven years.

High throughput screening market is segmented on the basis of types of products, type of technology used, end use and applications. Products available in the market are reagents and media, equipments, consumables, instruments, accessories, and services. Equipments and instruments are expected to witness a significant growth in demand due to their increasing use in drug discovery processes, superior performance, and reduced system cost. High throughput screening products find applications in R&D projects for target identification, primary screening, toxicology, stem cell biology, and others. Depending on the end use of high throughput screening the market is divided into biotechnology and pharmaceutical companies, government and academic institutes, and contract research organizations (CROs). On the basis of technology used, the market consists of label-free technology, cell-based assays, ultra high throughput screening, bioinformatics, and lab-on-a chip technology. Cell based assay segment accounted for the largest market share in 2014 owing to increasing usage of cell based screening assays in compound screening. While, label free technology is expected to be the fastest growing segment due to its increasing adoption rate in high throughput screening laboratories. Development of various orthogonal high throughput screening arrays such as chemiluminescence assay and miniaturized cell viability assay which are used in the identification of triage cytotoxic compounds, high throughput cellular microarrays, increasing use in toxicology and stem cell research, adoption of open innovative models, and automation of throughput screening techniques such as robot based workstations, database system, HTS software and robotics arms by biopharmaceutical companies for efficient and cost effective high throughput screening are factors expected to significantly drive the HTS market throughout the forecast period.

Geographically, high throughput screening market is divided into North America, Europe, Asia-Pacific, Latin America and MEA. In 2014, North America accounted for the largest market share owing to increasing application of cell line and cell culture techniques in cancer research, increasing quality of infrastructure for laboratory and clinical research, and increasing adoption of low cost throughput techniques in clinical diagnostic laboratories. Asia Pacific region is expected to grow at a significant rate during the forecast period owing to the technological development of emerging economies such China and India. This expected growth is attributed for by increasing development and production of vaccines, drugs, & new biologics, increasing government and corporate investment in the biotechnology and pharmaceutical sector, increasing median age of the population and presence of high unmet market demand. Furthermore, strengthening healthcare framework for treatment of infectious and high risk diseases, a number of investment opportunities in these immature markets, growing prevalence of chronic diseases, and increasing number of diagnostic laboratories in the region are also expected to drive demand in the high throughput screening market. Major participants in the market are expanding by geographical expansions, strategic alliances, innovations, acquisitions and partnerships with diagnostic laboratories, hospitals, and clinics. High throughput screening market is highly competitive owing to emergence of new entrants in the market and the presence of well established firms. The key participants in the high throughput screening market include Aurora Biomed Inc., Beckman Coulter, Inc., Agilent Technologies Inc., Life Technologies Corporation, Luminex Corporation, Roche Applied Sciences and Sigma-Aldrich Corporation.